[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641035":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":30,"centralContacts":38,"locations":30,"responsibleParty":46,"collaborators":30,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":30,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":30,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":72,"whyStopped":30,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":30},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"dexmedetomidine","EXPERIMENTAL","Dexmedetomidine 0.3mcg \u002Fkg over diluted in 10 ml 0.9% Na cl over 10 min and 10 min before end of surgery",[13],"Drug: Dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":17},"Propofol plus lidocaine","Propofol 2mg\u002Fkg plus lidocaine 1mg\u002Fkg over 10 min and 10 min before end of surgery",[18],"Drug: Propofol",{"label":20,"type":21,"description":22,"interventionNames":23},"placebo","PLACEBO_COMPARATOR","receive placebo 10 ml 0.9% Nacl over 10 min and 10 min before end of surgery",[24],"Drug: Placebo",[26,31,35],{"type":27,"name":28,"description":11,"armGroupLabels":29,"otherNames":30},"DRUG","Dexmedetomidine",[9],null,{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Propofol","Propofol 2mg\u002Fkg plus lidocaine 1mg\u002Fkg over 10 min and 10 min before end of surgery.",[15],{"type":27,"name":36,"description":22,"armGroupLabels":37,"otherNames":30},"Placebo",[20],[39,44],{"name":40,"role":41,"phone":42,"phoneExt":30,"email":43},"taher mohamed, residant","CONTACT","01120799228","taher2014mohamed@yahoo.com",{"name":45,"role":41,"phone":30,"phoneExt":30,"email":30},"elhadad ali mousa, professor",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","Taher Mohamed Aboelyamin","Resident of Anesthesiology, Surgical ICU and Pain Medicine","100641035","phase-4-dexmedetomidine-vs-propofol-lidocaine-mixture-in-preventing-the-post-operative-emergence-agitation-following-sevoflurane-anasthesia-100641035",false,"NCT07601698","Dexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia","The Efficacy of Dexmedetomidine Versus Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anesthesia in Pediatric Ophthalmic Surgeries , A Prospective Randomized Comparative Controlled Study","Inclusion Criteria:\n\n* patients aged 2-8 years .\n* ASA physical status I-II.\n* Scheduled for elective surgeries under general anesthesia with sevoflurane\n\nExclusion Criteria:\n\n* History of psychiatric illness or cognitive impairment.\n* Known allergy to study drugs.\n* Severe cardiovascular, hepatic, or renal disease.\n* Chronic use of sedatives or opioids.",true,"ALL","2 Years","8 Years",{"count":62,"type":63},200,"ESTIMATED","INTERVENTIONAL",[66],"PHASE4","Primary we will Compare the Efficacy between Dexmedetomidine and \"Propofol-lidocaine\" mixture in preventing the post operative emergence agitation following sevoflurane anasthesia in pediatric ophthalmic surgeries Secondary we will evaluate time of extubation, time of orientation, Hemodynamic variables, Visual analog scale ( VAS), facial expressions scale , Adverse events",[69],"Emergence Agitation",[71],"EA","NOT_YET_RECRUITING","2026-05-19",{"date":75,"type":76},"2026-05-22","ACTUAL",{"date":78,"type":63},"2026-05-01",{"date":80,"type":63},"2026-12",{"name":5,"class":6}]